Research programme: synovium-derived mesenchymal stem cells - Two Cells

Drug Profile

Research programme: synovium-derived mesenchymal stem cells - Two Cells

Alternative Names: gMSC®1; synovium-derived MSC - Two Cells

Latest Information Update: 08 Jun 2016

Price : $50

At a glance

  • Originator Two Cells
  • Class Stem cell therapies
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cartilage disorders

Most Recent Events

  • 05 Jun 2017 Twocells company plans a phase III trial for Cartilage disorders in Japan (JapicCTI-173603)
  • 25 Apr 2016 Chugai Pharmaceutical in-licenses Synovium-derived mesenchymal stem cells from Two Cells for development in Japan
  • 25 Apr 2016 Early research in Cartilage disorders in Japan (Parenteral) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top